Adalimumab is approved for the treatment of hidradenitis suppurativa (HS), plaque psoriasis, and other inflammatory conditions.
Our objective was to examine the safety of adalimumab administered every other week (EOW) and every week (EW) in patients with HS and psoriasis and to investigate informative data from non-dermatologic indications.
The second edition of a concise yet thorough illustrated review of the diagnosis and treatment of many forms of psoriasis now includes the many new therapies available and in development, as well as more material on psoriasis as a systemic disease and on comorbidities. This will be of interest to all dermatologists in training and practice, as well as primary care physicians.
Adopting these healthy habits can go a long way in reducing your risk for psoriasis complications and feeling better overall.
The key to successful psoriasis management is working with your doctor to find a treatment plan that’s right for you and then sticking to that plan. But your role in treatment doesn’t stop with medication. Making certain lifestyle changes is important too....